New diabetes treatment guidelines released
By Kim, Jin-Gu | translator Kim, Jung-Ju
23.05.12 12:09:22
가나다라
0
The Korea Diabetes Association discusses the new guidelines at its 2023 Annual Fall Conference
“GLP-1 analogues recommended before basal insulin when used in combination with injection therapy”
“SGLT-2 inhibitors to be used first when a patient has heart failure, regardless of HbA1c levels”
The status of GLP-1 analogues and SGLT-2 inhibitors has risen further in Korea’s new diabetes treatment guidelines.
In the revised guidelines, when considering options to use in combination with injection therapy, GLP-1 analogues were recommended over basal insulin, and SGLT-2 inhibitors were recommended first for diabetic patients with heart failure, kidney disease, or cardiovascular disease.
▲Kyu-Chang Won, Chairman of KDA (Endoctriology, Yeungnam University Hospital) is introducing KDA
On the 12th, Korean Diabetes Association introduced the key contents of its ‘KDA clinical practice guidelines for diabetes: 8th edition’ at the 2023 Spring Conference of the Korean Diabetes Association that was held at the Kimdaejung Convention Center in Gwangju. The KDA publishes treatment guid
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)